簡介：
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia. Its product pipeline includes ZolpiMist, a oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia; ArTiMist, a sub-lingual spray for the treatment of p. falciparum severe paediatric malaria; and Midazolam, a flavoured oral spray formulation for the treatment of epileptic seizures and pre-procedure anxiety in imaging and dental procedures under the Versed brand. The company's product pipeline also comprises Sumatriptan, an oral spray formulation for the treatment of acute migraine; Ondansetron, a mint-flavored oral spray formulation for the treatment of chemotherapy induced nausea and vomiting and postoperative nausea and vomiting; Sildenafil, an oral spray formulation for the treatment of erectile dysfunction. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH for ZolpiMist oral spray; and feasibility and option agreement with Zelda Therapeutics Ltd for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. to co-develop a consumer product for the pediatric market. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.